We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of melphalan‐ And busulfan‐based myeloablative conditioning in children undergoing allogeneic transplantation for acute myeloid leukemia or myelodysplasia.
- Authors
Oshrine, Benjamin; Adams, Lauren; Nguyen, Anh Thy H.; Amankwah, Ernest; Shyr, David; Hale, Gregory; Petrovic, Aleksandra
- Abstract
Background: The optimal conditioning regimen for alloHCT in children with myeloid malignancies remains undefined. Procedure: We performed a retrospective review of children undergoing alloHCT for AML and MDS over a 10‐year period (2008‐2018) at our institution, comparing the outcomes of recipients of either a myeloablative busulfan‐ or reduced toxicity mel/thio‐based conditioning regimen. Results: A total of 49 patients underwent alloHCT for AML/MDS (mel/thio, N = 21; busulfan, N = 28). Mel/thio recipients were selected due to pretransplant comorbidities. Recipients of mel/thio were more likely to have t‐AML, and less likely to have MRD <0.1% at the time of alloHCT (57.1% vs 82.1%). Graft failure was more common in busulfan recipients; engraftment kinetics were similar between groups. Sinusoidal obstructive syndrome was diagnosed in 21% of busulfan and no mel/thio recipients (P =.03). One patient in each group died from TRM. Relapse incidence was comparable (mel/thio—29% vs busulfan—32%); however, relapse occurred significantly later in recipients of mel/thio conditioning (median d + 396 vs d + 137; P =.01). As a result, there was a trend toward improved OS at 1 and 3 years in mel/thio recipients (95% vs 74%, P =.06; and 75% vs 50%, P =.11; respectively). Conclusion: In our single institution, when compared to myeloablative busulfan‐based conditioning, use of a mel/thio‐based reduced toxicity regimen resulted in comparable outcomes, despite higher risk patient and disease characteristics. Mel/thio recipients had both more comorbidities and higher risk disease profile, which did not translate into higher rates of either TRM or relapse.
- Subjects
ACUTE myeloid leukemia; TOTAL body irradiation; BUSULFAN; TRANSPLANTATION of organs, tissues, etc.; COMORBIDITY
- Publication
Pediatric Transplantation, 2020, Vol 24, Issue 4, p1
- ISSN
1397-3142
- Publication type
Article
- DOI
10.1111/petr.13672